Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) saw a significant increase in short interest in June. As of June 15th, there was short interest totalling 2,200,000 shares, an increase of 10.0% from the May 31st total of 2,000,000 shares. Based on an average trading volume of 981,200 shares, the short-interest ratio is presently 2.2 days. Currently, 3.6% of the company’s stock are short sold.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on CLBT shares. Needham & Company LLC raised their price target on shares of Cellebrite DI from $13.50 to $14.00 and gave the stock a “buy” rating in a report on Friday, May 24th. JPMorgan Chase & Co. raised their price target on shares of Cellebrite DI from $12.00 to $14.00 and gave the stock an “overweight” rating in a report on Friday, May 24th. Lake Street Capital started coverage on shares of Cellebrite DI in a report on Friday, April 19th. They issued a “buy” rating and a $13.00 price target for the company. Craig Hallum raised their price target on shares of Cellebrite DI from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Monday, April 1st. Finally, William Blair raised shares of Cellebrite DI from a “market perform” rating to an “outperform” rating in a report on Wednesday, March 13th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $13.17.
Get Our Latest Stock Report on CLBT
Institutional Inflows and Outflows
Cellebrite DI Price Performance
Shares of Cellebrite DI stock opened at $12.14 on Tuesday. The firm has a fifty day moving average price of $11.33 and a 200 day moving average price of $10.52. Cellebrite DI has a 1 year low of $6.36 and a 1 year high of $12.67. The stock has a market cap of $2.50 billion, a PE ratio of -20.93, a price-to-earnings-growth ratio of 1.63 and a beta of 1.50.
Cellebrite DI (NASDAQ:CLBT – Get Free Report) last released its quarterly earnings data on Thursday, May 23rd. The company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. Cellebrite DI had a negative net margin of 32.57% and a positive return on equity of 417.94%. The company had revenue of $89.60 million during the quarter, compared to analysts’ expectations of $85.34 million. During the same quarter in the previous year, the company earned $0.03 earnings per share. The firm’s revenue for the quarter was up 25.8% on a year-over-year basis. As a group, equities analysts expect that Cellebrite DI will post 0.34 EPS for the current year.
About Cellebrite DI
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Further Reading
- Five stocks we like better than Cellebrite DI
- ETF Screener: Uses and Step-by-Step Guide
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- How to Calculate Options Profits
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- Where to Find Earnings Call Transcripts
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.